Literature DB >> 24272364

Evaluation of cytology and visual triage of human papillomavirus-positive women in cervical cancer prevention in India.

Richard Muwonge1, Ramani S Wesley, Bhagwan M Nene, Surendra S Shastri, Kasturi Jayant, Sylla G Malvi, Somanathan Thara, Rengaswamy Sankaranarayanan.   

Abstract

Although virtually all cervical cancers and most cervical intraepithelial neoplasia (CIN) are caused by persistent human papillomavirus (HPV) infection, only a small proportion of HPV-positive women have or will develop CIN. Triaging HPV-positive women has been suggested to reduce the false-positive rate and proportion of women referred for CIN confirmation and/or treatment. In two cross-sectional studies and one randomized trial in India, we evaluated the impact of using cytology or visual inspection with acetic acid (VIA) to triage HPV-positive women on the proportion of women who would be referred for CIN confirmation and on the detection rates of high-grade CIN. We present the numbers of HPV test-positive women found and the CIN detected among them. We further assess the proportions that would be referred for CIN confirmation with colposcopy/biopsy and CIN that would be detected if cytology triage or VIA triage were used. Using cytology triage at atypical squamous cells of undetermined significance threshold or VIA triage reduced referrals for colposcopy by about 62% and 59%, respectively (p-value = 0.012), but missed around 16% and 18%, respectively, of the high-grade CIN (p-value = 0.539) indicating similar performance of both triaging approaches. The choice of a triage test in different low- and middle-income countries (LMIC) would depend on the availability and affordability in the particular setting. Cytology triage may be considered in settings where adequate infrastructure exists, whereas VIA triage may be suitable in settings with limited or no cytology infrastructure.
© 2013 UICC.

Entities:  

Keywords:  HPV testing; cervical intraepithelial neoplasia; cytology; triage; visual inspection with acetic acid

Mesh:

Substances:

Year:  2013        PMID: 24272364     DOI: 10.1002/ijc.28627

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Magnivisualizer in the early detection of cervical neoplasia.

Authors:  Rengaswamy Sankaranarayanan
Journal:  J Gynecol Oncol       Date:  2014-10       Impact factor: 4.401

2.  Effect of TLR4 on the growth of SiHa human cervical cancer cells via the MyD88-TRAF6-TAK1 and NF-κB-cyclin D1-STAT3 signaling pathways.

Authors:  Li Ma; Li Feng; Xiaoping Ding; Yongwang Li
Journal:  Oncol Lett       Date:  2018-01-16       Impact factor: 2.967

Review 3.  Cervical cancer screening in developing countries at a crossroad: Emerging technologies and policy choices.

Authors:  Rosa Catarino; Patrick Petignat; Gabriel Dongui; Pierre Vassilakos
Journal:  World J Clin Oncol       Date:  2015-12-10

4.  Cervical Cancer Screening in Low Resource Settings: Cytology versus HPV Triage for VIA Positive Women.

Authors:  Gauravi A Mishra; Sharmila A Pimple; Subhadra D Gupta
Journal:  Int J Prev Med       Date:  2019-08-12

5.  Multicentric study of cervical cancer screening with human papillomavirus testing and assessment of triage methods in Latin America: the ESTAMPA screening study protocol.

Authors:  Maribel Almonte; Raúl Murillo; Gloria Inés Sánchez; Paula González; Annabelle Ferrera; María Alejandra Picconi; Carolina Wiesner; Aurelio Cruz-Valdez; Eduardo Lazcano-Ponce; Jose Jerónimo; Catterina Ferreccio; Elena Kasamatsu; Laura Mendoza; Guillermo Rodríguez; Alejandro Calderón; Gino Venegas; Verónica Villagra; Silvio Tatti; Laura Fleider; Carolina Terán; Armando Baena; María de la Luz Hernández; Mary Luz Rol; Eric Lucas; Sylvaine Barbier; Arianis Tatiana Ramírez; Silvina Arrossi; María Isabel Rodríguez; Emmanuel González; Marcela Celis; Sandra Martínez; Yuly Salgado; Marina Ortega; Andrea Verónica Beracochea; Natalia Pérez; Margarita Rodríguez de la Peña; María Ramón; Pilar Hernández-Nevarez; Margarita Arboleda-Naranjo; Yessy Cabrera; Brenda Salgado; Laura García; Marco Antonio Retana; María Celeste Colucci; Javier Arias-Stella; Yenny Bellido-Fuentes; María Liz Bobadilla; Gladys Olmedo; Ivone Brito-García; Armando Méndez-Herrera; Lucía Cardinal; Betsy Flores; Jhacquelin Peñaranda; Josefina Martínez-Better; Ana Soilán; Jacqueline Figueroa; Benedicta Caserta; Carlos Sosa; Adrián Moreno; Juan Mural; Franco Doimi; Diana Giménez; Hernando Rodríguez; Oscar Lora; Silvana Luciani; Nathalie Broutet; Teresa Darragh; Rolando Herrero
Journal:  BMJ Open       Date:  2020-05-24       Impact factor: 2.692

6.  Performance of Two-Stage Cervical Cancer Screening With Primary High-Risk Human Papillomavirus Testing in Women Living With Human Immunodeficiency Virus.

Authors:  Rebecca Luckett; Neo Mogowa; Howard J Li; Adrienne Erlinger; Michele R Hacker; Katharine Esselen; Sarah Feldman; Roger Shapiro; Chelsea Morroni; Doreen Ramogola-Masire
Journal:  Obstet Gynecol       Date:  2019-10       Impact factor: 7.661

7.  Resources Required for Cervical Cancer Prevention in Low- and Middle-Income Countries.

Authors:  Nicole G Campos; Monisha Sharma; Andrew Clark; Jane J Kim; Stephen C Resch
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

8.  Evaluation of human-papillomavirus testing and visual inspection for cervical cancer screening in Rwanda.

Authors:  M Chantal Umulisa; Silvia Franceschi; Iacopo Baussano; Vanessa Tenet; Mathilde Uwimbabazi; Belson Rugwizangoga; Daniëlle A M Heideman; Anne M Uyterlinde; Teresa M Darragh; Peter J F Snijders; Felix Sayinzoga; Gary M Clifford
Journal:  BMC Womens Health       Date:  2018-04-24       Impact factor: 2.809

9.  Triage of Women Testing Positive With the careHPV Test on Self-Collected Vaginal Samples for Cervical Cancer Screening in a Low-Resource Setting.

Authors:  Usha Rani Poli; Swarnalata Gowrishankar; Meenakshi Swain; Jose Jeronimo
Journal:  J Glob Oncol       Date:  2017-09-29

10.  Community-based HPV self-collection versus visual inspection with acetic acid in Uganda: a cost-effectiveness analysis of the ASPIRE trial.

Authors:  Alex K Mezei; Heather N Pedersen; Stephen Sy; Catherine Regan; Sheona M Mitchell-Foster; Josaphat Byamugisha; Musa Sekikubo; Heather Armstrong; Angeli Rawat; Joel Singer; Gina S Ogilvie; Jane J Kim; Nicole G Campos
Journal:  BMJ Open       Date:  2018-06-12       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.